In a bid to bolster its pipeline, Sanofi has partnered with Skyhawk Therapeutics to discover, develop, and commercialise small molecule therapeutics for immunology and oncology targets. The deal, which is worth up to US$2.54 B, gives Sanofi access to Skyhawk’s SkySTAR® platform that aims to correct the underlying genetics of disease at the mRNA level. Interestingly, the deal comes six months after Sanofi’s cancer drug, iniparib (BSI-201), failed to meet survival and progression-free survival goals.